2017
DOI: 10.1097/mjt.0000000000000284
|View full text |Cite
|
Sign up to set email alerts
|

Combination Therapies of Diacerein and Febuxostat Inhibit IL-1β Responses and Improve Clinical Symptoms in Patients With Refractory Gout

Abstract: There are several therapeutic strategies available for the treatment of an acute gout attack and the prevention of recurrent gout flares, and they include nonsteroid anti-inflammatory drugs. This prospective study was aimed at evaluating the efficiency and safety of diacerein in combination with febuxostat on urate control, global assessments of disease activity, self-monitored gouty acute flare times, inflammatory markers, and clinical symptoms associated with their life quantity in patients with refractory g… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(4 citation statements)
references
References 20 publications
0
4
0
Order By: Relevance
“…The occurrence of gout can bring severe pain to patients. If effective treatment measures are not taken, the acute attacks of gout in patients are more frequent, which is the main factor that reduces the quality of life of patients 27 . Maekawa et al 28 .…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…The occurrence of gout can bring severe pain to patients. If effective treatment measures are not taken, the acute attacks of gout in patients are more frequent, which is the main factor that reduces the quality of life of patients 27 . Maekawa et al 28 .…”
Section: Discussionmentioning
confidence: 99%
“…26 The results of this study showed that after 6 months of treatment, the levels of TNF-a, IL-1β, and IL-18 in the study group were lower than those If effective treatment measures are not taken, the acute attacks of gout in patients are more frequent, which is the main factor that reduces the quality of life of patients. 27 Maekawa et al 28 suggested that non-bisphosphonate combined with allopurinol can relieve pain and have significant therapeutic effects in patients with refractory gout. The results of this study showed that after 6 months of treatment, the degree of pain in the study group was lower than that in the control group (p < .05), suggesting that non-bisphosphonate combined with a low-purine diet can effectively alleviate the degree of pain in gout patients.…”
Section: Ta B L Ementioning
confidence: 99%
“…The benefits of dotinurad as an SURI, which inhibits NLRP3 inflammasomes and URAT1, are evident. Several non-SURIs have been reported to inhibit NLRP3 inflammasomes 23,24,28) , including benzbromarone, which is commercially available ( Figures 5, 6 and 7). However, benzbromarone also strongly inhibits ABCG2 16) , which plays a role as a gatekeeper against xenobiotics and regulates pharmacokinetics and efficacy of substrate drugs for ABCG2.…”
Section: Discussionmentioning
confidence: 99%
“…Urate-lowering anti-flare therapy aims to reduce both serum uric acid levels and gout flares by uricosuric action and the blocking of urate crystal-stimulated release of IL-1β from neutrophils or macrophages, respectively 23,24) . In the present study, we investigated the effects of dotinurad, an SURI, on the stimulation of NLRP3 inflammasomes by MSU crystals in LPS-primed mouse J774 macrophages, which ultimately suggested that this drug can inhibit the MSU crystal-stimulated IL-1β release from macrophages by activating NLRP3 inflammasomes.…”
Section: Introductionmentioning
confidence: 99%